Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–64
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
History of migraine with or without aura for \>1 year and with ≥4 and ≤14 migraine days per month in the 3 months prior to study
Male, female not of reproductive potential, or female of reproductive potential who is not pregnant by pregnancy test and agrees to use acceptable contraception
You may not be if
Pregnancy, breast-feeding, or expecting to become pregnant
Planning to donate egg or sperm during the study or within 90 days after last dose of study medication
Basilar or hemiplegic migraine headache
\>50 years old at the age of migraine onset
≥15 headache-days per month or medication taken for acute migraine or other headaches on more than 10 days per month in any of the three months prior to study
Migraine prophylactic medication (defined as medication taken daily to prevent migraines) taken in the 30 days prior to study
History of narcolepsy, cataplexy, circadian rhythm disorder, parasomnia, sleep related breathing disorder, restless legs syndrome, periodic limb movement disorder, excessive daytime sleepiness or difficulty sleeping due to a medical condition (e.g., asthma, gastroesophageal reflux disease, etc.)
Clinical, laboratory, or electrocardiogram (ECG) evidence of uncontrolled hypertension, uncontrolled diabetes, human immunodeficiency virus (HIV) disease, or significant pulmonary, renal, hepatic, endocrine, or other systemic disease
Myocardial infarction, unstable angina, coronary artery bypass surgery, or other revascularization procedure, stroke, or transient ischemic attack within 3 months of study
Other confounding pain syndromes (i.e., condition requiring daily use of opioids), psychiatric conditions such as uncontrolled major depression, dementia or significant neurological disorders other than migraine
Imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicidality Severity Rating Scale (C-SSRS), or of harm to others. Exclude any prospective participant reporting suicidal ideation with intent, with or without a plan in the past 2 months or suicidal behavior in the past 6 months
History of malignancy ≤5 years prior to study, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
History of hypersensitivity to more than two chemical classes of drugs, including prescription and over-the-counter medications
Recent history (within the past 1 year) or current evidence of drug or alcohol abuse or "recreational use" of illicit drugs or prescription medications
Donated blood products or has had phlebotomy of \>300 ml within 8 weeks of study, or intends to donate blood products or receive blood products within 30 days before study and throughout study
Consumption of 3 or more alcoholic drinks per day
Body Mass Index \>40 kg/m\^2
History of transmeridian travel (across \>3 time zones) or shift work (defined as permanent night shift or rotating day/night shift work) within the past 2 weeks or anticipates needing to travel (across \>3 time zones) at any time during the study.
Clareo Health | A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)
